Early detection of brain cancer will help saving lives. The currently available diagnostic techniques are not robust and expensive. Therefore, it is necessary to develop cost effective, minimally invasive, and highly sensitive analytical tools to identify brain tumors at an early stage. In this study we are investigating metabolism based biomarkers in platelets derived from low grade glioma II, glioblastoma, and healthy patients identified by nuclear magnetic resonance (NMR) spectroscopy. The platelet metabolites - glucose, citrate, and succinate are determined to be promising candidates for identifying and differentiating different stages of brain tumors with implication of employing simple blood based NMR metabolomics for early detection of brain cancer.